vaccine development

ARKO Labs, Ltd. develops, manufactures, and markets vaccines for the swine and poultry industries. Located in Jewell, Iowa, the biologics company focuses on products that protect against diseases reducing livability and growth rate in swine and poultry, emphasizing oral/waterline delivery and modified live products. It has three on-staff veterinarians providing technical support and consultation.

autogenous vaccine productiontechnical support and consultationvaccine manufacturing

Attana AB is a Swedish life science company that provides the life science community with analytical instruments and services for bioanalysis. Its proprietary biosensor technology measures molecular interactions in real time in biologically relevant environments such as blood, plasma, living cells and tissue, helping drug developers validate, select and optimize drug candidates for Phase I and Phase II studies. The company also offers contract research (CRO) services and diagnostics through Attana Diagnostics and Attana Virus Analytics (AVA).

antibody developmentbiosensor technologycell-based assaysdrug discovery and developmentimmunogenicity studiesinteraction analysiskinetic analysislabel-free analysistranslational research

Biological Mimetics, Inc. (BMI) is a privately-held biomedical company located in Frederick, Maryland, USA, formed in 1996 to commercialize innovative pharmaceutical products that combat resistant and emerging diseases in human and veterinary medicine. Its mission is to join biology and engineering to identify and prevent global infections. BMI develops proprietary vaccine platforms (Immune Refocusing Technology and the 'ultra' UVC irradiation vaccine platform) and the FAST chip diagnostic device.

artificial intelligence applicationsbioinformatic analysiscomputational biologyCRISPR diagnosticsisothermal RPA amplificationUV irradiation inactivation

Centivax is a clinical-stage company on a mission to accelerate the world's transition to a post-pathogen humanity. Its first broad-spectrum vaccine is in Phase 1 clinical development for prevention of all influenza, and was awarded a Gates Foundation Grand Challenge: End the Pandemic Threat. The company was featured in the Netflix docuseries Pandemic: How to Prevent an Outbreak.

clinical-stage research

Design-Zyme LLC is a specialized vertically-integrated biotech founded in 2015 at the KU Innovation Park, Lawrence, Kansas. It has developed a patented multivalent vaccine platform delivering multivalent hapten vaccines for small molecule targets or multivalent protein immunogen vaccines for pathogenic threats. Its pipeline addresses opioid use disorder (DZ-XNF1), emerging drug threats in West & Central Africa (DZ-KU1), Lyme disease (DZ-LD1), and fescue toxicosis in livestock (DZ-FT1).

adjuvant solutionsdata-driven researchhapten-based vaccine developmentmultivalent nanoparticle approaches

Dynavax Technologies is a commercial-stage biopharmaceutical company committed to developing and commercializing novel vaccines to help protect the world against infectious diseases by utilizing proven, innovative adjuvant technology. Its products include HEPLISAV-B, an adult hepatitis B vaccine, and the CpG 1018 adjuvant.

adjuvant technologymanufacturingToll-like Receptor (TLR) stimulation

Emervax is a vaccine company founded by leaders in RNA biochemistry and infectious diseases to chart a new course in vaccination. Leveraging circRNA technology, advanced purification methods and innovative delivery strategies, it focuses on creating groundbreaking vaccines against viruses and difficult-to-treat cancers. Its modular multipurpose vaccine platform addresses global health challenges with next-generation vaccines for emerging viruses and chronic diseases.

advanced purification methodscircRNA technologyinnovative delivery strategies

Eveliqure Biotechnologies is an innovative biotech company developing novel vaccines for the prevention of diarrhoeal diseases both for travellers and people living in endemic regions of low- and middle-income countries. It has developed a vaccine technology platform based on a live attenuated vaccine strain of the bacterium Shigella, engineered to induce broad protection against different species and serotypes, and expressing non-shigella derived antigens for protection against multiple pathogens. Its first-generation vaccine candidate, ShigETEC, target

antigen expressionlive attenuated vaccine strain engineering

FluGen, Inc. is developing a more effective vaccine in the fight against influenza and respiratory disease. Its M2SR Vaccine Platform is a clinically-tested vaccine candidate addressing unmet needs in flu prevention, including consistent efficacy, annual virus drift, and shedding. The flagship candidate M2SR is an intranasal, supra-seasonal flu vaccine that stimulates mucosal, humoral, and cellular immunity. Long-term R&D plans include potential application against SARS-CoV-2 (COVID-19) and other respiratory diseases such as RSV.

clinical trialsintranasal vaccinepre-clinical research

GSK is a global biopharma company that discovers, develops and delivers medicines and vaccines. It focuses on four core therapeutic areas: respiratory, immunology and inflammation; oncology; HIV; and infectious diseases. Its purpose is to unite science, technology and talent to get ahead of disease together, aiming to positively impact the health of 2.5 billion people by the end of the decade.

Chemical Manufacturing and Controls (CMC)Genomic sciencesMedicine manufacturingresearch and development

Immunartes is a biotechnology company developing therapies that neutralize Staphylococcus aureus immune evasion to restore host defense and prevent serious S. aureus disease. Its platform targets the immune-evasion pathway and supports coordinated vaccine and monoclonal antibody (mAb) programs aimed at prevention, currently in preclinical discovery and IND-enabling stages.

animal modelsantibody characterizationmonoclonal antibody developmentpreclinical researchtranslational immunologyvaccine antigen evaluation

Immunova Therapeutics is a Los Angeles-based company focused on cancer immunotherapy, working on technologies including CAR-T cells, TCR-T cells, antibodies, and vaccines. The site describes CAR-T cells engineered to express synthetic receptors and TCR-T therapy that introduces tumor-specific T cell receptors into patient T cells.

antibody developmentCAR-T cell engineeringTCR-T therapy

Irazu Oncology, LLC is a clinical-stage biotech founded in 2022 developing off-the-shelf cancer immunotherapies built on a proprietary bacterial outer membrane vesicle (OMV) platform. The platform creates customized, self-adjuvanted mono/multivalent therapeutic vaccines carrying tumor antigens and immune-activating signals. Its lead program, IRZ-03, is a first-in-class multimodal OMV immunotherapy targeting CEA, MUC1, and PD-L1 for checkpoint inhibitor-refractory solid tumors.

bacterial outer membrane vesicle (OMV) platformIND-enabling studiesscalable bacterial fermentation